CSL advances its vision for a more sustainable future by setting new, tangible targets for reducing carbon emissions
Melbourne, 17 August 2022 – CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for reducing carbon emissions.
As part of the company’s broader sustainability strategy to build a more sustainable future for employees, communities, patients and donors, CSL is announcing new carbon emission reduction targets that will serve as a transparent roadmap for decarbonise global operations by reducing direct and indirect carbon emissions.
By 2030, the company:
- It is targeting a 40% reduction in absolute Scope 1 and 2 emissions against a baseline of average annual emissions over FY19-21; AND
- It aims to ensure that suppliers contributing 67% of Scope 3 emissions have set Scope 1 and 2 reduction targets, in line with the science-based targets initiative.
Both targets are in line with the goal of limiting global warming to 1.5 degrees Celsius. Importantly, the timeframes are also aligned with CSL 2030 business strategy, ensuring that targets are incorporated into our detailed operational plans. Achieving the reduction of scope 1 and 2 emissions will occur through four main mitigation levers:
- increasing energy efficiency;
- a push towards more renewable energy;
- switching fuels to less carbon intensive energy sources; AND
- redesigning some of its production sites.
CSL recognizes that the responsible management and efficient use of natural resources is key to the company’s sustainable growth and its ability to provide an efficient and reliable supply of life-saving medicines.
“For more than a century, CSL has earned trust by striving to deliver on our promise to improve patients’ lives and protect public health,” said CSL Chief Executive Officer and Managing Director Paul Perreault. “We intend to continue to earn this trust, as a company dedicated to a healthier world.”
Aspects of this work are already well underway. CSL facilities in Liverpool, United Kingdom, and Bern, Switzerland, are currently renewable energy sources. CSL’s new research and development complexes in Marburg, Germany and Waltham, Massachusetts will feature modern sustainable design features, as will CSL’s new corporate headquarters building in Melbourne, Australia.
In addition to reducing carbon emissions, CSL is prioritizing the integration of environmental considerations into key business decisions; minimizing end-to-end waste generation through removal, reduction and recycling; and reducing waste in our supply chain.
The specific targets build on the previously announced strategy serving as a tangible and transparent roadmap for decarbonizing CSL’s operations by reducing the company’s direct and indirect emissions footprint. They are a further evolution in CSL’s responsibility to deliver our therapeutics and vaccines in a more efficient, comprehensive and environmentally friendly manner.
“Our ongoing efforts and new sustainability targets demonstrate our promise to protect people and our planet. As a scientific and data-driven company, we are taking specific measures and analysis to ensure we continue to set and meet the right targets going forward,” said CSL Chief Financial Officer Joy Linton. “It’s all part of CSL’s Promise to drive a more sustainable future.”
For more information visit: https://investors.csl.com/site/investors/sustainability
*** Ends ***
Media Contact – Australia
Jimmy Baker
[email protected]
+61 450 909 211
Contact Media – Rest of the World
Tom Hushen
[email protected]
267-769-6728
About CSL
CSL Limited (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those treating hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our inception in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides life-saving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL.
For more information about CSL Limited, visit www.CSL.com.
